QUANTICATE INTERNATIONAL LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Moore NHC Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. QUANTICATE INTERNATIONAL LIMITED · parent
   1. Quanticate Polska Sp.z.o.o. 100% · Poland · Contract Research
   2. Quanticate (Pty) Ltd 100% · South Africa · Contract Research
   3. Quanticate Pharma Service Inc 100% · Canada · Contract Research
   4. Quanticate India Private Limited 100% · India · Contract Research

Significant events

• “2024 was a difficult year for the CRO sector and for the Group. Major pharma cost-reduction programmes, increased insourcing by certain customers and aggressive pricing from lower-cost providers impacted volumes and revenue.”
• “We acted decisively to protect capability and liquidity, including further streamlining of indirect costs, reducing administrative costs by approximately £1 million compared to the previous year, continuing our fiscal discipline. Our strategy of expanding our operations in cost-effective locations, particularly in India, positioned us well to sustain competitive pricing, helping mitigate some margin pressures. This continued discipline enabled us to preserve liquidity, with cash reserves rising to £6.2 million at year-end (2023: £4.9 million).”
• “Average headcount reduced to 51 (2023: 66) through attrition and some redundancies.”
• “Notwithstanding the downturn, commercial traction improved in 2025: a new strategic client was signed; we are in final negotiations with another prospective strategic customer; and an existing large pharma client is evaluating a team expansion with Quanticate.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +26.3%

  £4,892,185 → £6,178,853

• Net assets

  -8.3%

  £7,200,792 → £6,601,437

• Employees

  -22.7%

  66 → 51

• Profit before tax

  -117.9%

  £4,731,361 → -£845,267

• Wages

  -18.1%

  £3,792,088 → £3,107,557

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers